静脉甘露醇对玻璃体切除眼与非玻璃体切除眼眼内压变化的影响:系统综述与荟萃分析
该系统综述与荟萃分析检索截至2024年3月1日的文献,纳入5项研究(玻璃体切除眼145眼、非玻璃体切除眼91眼),评估静脉甘露醇对眼内压的影响。结果显示甘露醇在多个时间点显著降低眼内压,玻璃体切除眼与非玻璃体切除眼之间眼内压变化无显著差异。作者认为甘露醇可用于眼科手术围手术期眼内压升高的急性管理,但需进一步随机对照试验。
要点
- 玻璃体切除眼在30分钟至4小时多个时间点眼内压显著降低,降幅16.7%至30.8%。
- 玻璃体切除眼与非玻璃体切除眼之间甘露醇降眼内压效果无显著差异。
- 纳入5项研究共玻璃体切除眼145眼、非玻璃体切除眼91眼,随机效应模型分析。
核心结论
- 静脉甘露醇可有效降低玻璃体切除眼与非玻璃体切除眼的眼内压,在眼科手术中及术后眼内压升高的急性管理中具有应用价值。
- 作者认为这些发现支持将甘露醇纳入围手术期管理方案,但需进一步随机对照试验及更广泛人群代表性的研究来优化用法并全面了解长期安全性和有效性。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、EMBASE、Scopus和Web of Science从建库至2024年3月1日的文献。
- 纳入随机对照试验、队列研究和病例对照研究,排除病例报告和综述文章。
- 共纳入5项研究,包括玻璃体切除眼145眼和非玻璃体切除眼91眼。
- 采用随机效应模型进行荟萃分析,使用R软件(V 4.3)进行统计分析。
主要发现
- 玻璃体切除眼在30分钟时均数比值(ROM)为0.81(95%CI:0.53;1.24),对应眼内压降低19%。
- 玻璃体切除眼在60分钟时ROM为0.833(95%CI:0.77;0.89),对应降低16.7%。
- 玻璃体切除眼在90分钟时ROM为0.757(95%CI:0.755;0.758),对应降低24.3%。
- 玻璃体切除眼在2小时时ROM为0.726(95%CI:0.642;0.820),对应降低27.4%;3小时时ROM为0.692(95%CI:0.600;0.797),对应降低30.8%;4小时时ROM为0.700(95%CI:0.363;1.350),对应降低30%。
- 玻璃体切除眼与非玻璃体切除眼比较,甘露醇给药后眼内压变化无显著差异。
关键数值与推荐
- 30分钟时间点纳入3项研究,其他所有时间点纳入2项研究。
- 玻璃体切除眼30分钟ROM 0.81(95%CI:0.53;1.24),60分钟ROM 0.833(95%CI:0.77;0.89),90分钟ROM 0.757(95%CI:0.755;0.758)。
- 玻璃体切除眼2小时ROM 0.726(95%CI:0.642;0.820),3小时ROM 0.692(95%CI:0.600;0.797),4小时ROM 0.700(95%CI:0.363;1.350)。
临床怎么用
- 作者认为静脉甘露醇可有效降低玻璃体切除眼与非玻璃体切除眼的眼内压,可用于眼科手术中及术后眼内压升高的急性管理。
- 作者认为这些发现支持将甘露醇纳入围手术期管理方案。
- 作者建议需进一步随机对照试验及更广泛人群代表性的研究来优化甘露醇用法并全面了解其长期安全性和有效性。
局限性
- 作者指出需要进一步研究,特别是随机对照试验和具有更广泛人群代表性的研究,以优化甘露醇的使用并充分了解其长期安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intraocular pressure (IOP) control is paramount during ophthalmic surgeries to ensure successful outcomes and prevent complications. Intravenous mannitol has been explored for its ability to manage IOP fluctuations in both vitrectomized and non-vitrectomized eyes. This meta-analysis aimed to assess the efficacy of mannitol in controlling IOP across these patient groups. DESIGN: Systematic review and meta-analysis. METHODS: A literature search was conducted across PubMed, EMBASE, Scopus, and Web of Science from inception up to March 1, 2024, focusing on studies investigating mannitol's impact on IOP in vitrectomized and non-vitrectomized eyes. Randomized controlled trials, cohort studies, and case-control studies were included, while case reports and review articles were excluded. The primary outcome was the change in IOP following mannitol administration. Meta-analysis was performed using a random-effects model. R software (V 4.3) was used for statistical analysis. RESULTS: Our search included five studies of both vitrectomized (145 eyes) and non-vitrectomized eyes (91 eyes). The meta-analysis demonstrated significant IOP reductions following mannitol administration across multiple time points. Three studies were included at 30 min and 2 studies at all other time points in the analysis. In vitrectomized eyes, notable decreases were observed: at 30 min, the Ratio of Means (ROM) was 0.81 (95% CI: 0.53; 1.24), indicating a 19% reduction; at 60 min, the ROM of 0.833 (95% CI: 0.77; 0.89) showed a 16.7% reduction; at 90 min, the ROM of 0.757 (95% CI: 0.755; 0.758) corresponded to a 24.3% reduction; at 2 h, the ROM of 0.726 (95% CI: 0.642; 0.820) reflected a 27.4% reduction; at 3 h, the ROM of 0.692 (95% CI: 0.600; 0.797) resulted in a 30.8% reduction; and at 4 h, the ROM of 0.700 (95% CI: 0.363; 1.350) indicated a 30% reduction. No significant changes were observed on IOP with mannitol administration when comparing vitrectomized versus non- vitrectomized eyes. CONCLUSION: Intravenous mannitol effectively reduces IOP in both vitrectomized and non-vitrectomized eyes, demonstrating its utility in the acute management of elevated IOP during and after ophthalmic surgeries. These findings support the integration of mannitol into perioperative care protocols. However, further research, particularly randomized controlled trials and studies with broader demographic representation, is needed to optimize mannitol's usage and fully understand its long-term safety and efficacy.
引用
- Serhan HA, Gupta PC, Khatib MN, et al. Effect of Intravenous Mannitol on Intraocular Pressure Changes in Vitrectomized and Non-Vitrectomized Eyes: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2024. PMID: 39033830. doi:10.1016/j.ajo.2024.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。